New mRNA shot aims to calm stubborn autoimmune diseases

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age range of 18-70 years old (including threshold), gender not limited; * 2\. KPS score\>60 points, life expectancy greater than 6 months; * 3\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel; * 4\. Those who can understand this experiment and have signed the informed consent form; * 5\. Before screening (at baseline), corresponding requirements should be met; * 6\. Diagnosed with recurrent or refractory immune related diseases, including systemic lupus erythematosus (SLE), autoimmune hepatitis, idiopathic inflammatory myopathy, scleroderma, etc. Exclusion Criteria: * 1\. Study participants who are allergic or hypersensitive to any component of the investigational drug, including those who are allergic to messenger RNA (mRNA) vaccines or other RNA LNP products. * 2\. Merge any active infections that require antibiotic treatment and have not been controlled for at least one week prior to administration. * 3\. Accompanied by other uncontrolled malignant tumors. * 4\. History of cardiovascular disease within the first 6 months of screening: NYHA defined grade III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant heart diseases. * 5\. New York Heart Association (NYHA) grade III-IV heart failure. * 6\. Hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus (HBV) DNA positive or titer higher than the detection threshold; Individuals with positive hepatitis C virus (HCV) antibodies and HCV RNA positivity or titers above the detection threshold; Human immunodeficiency virus (HIV) antibody positive individuals; Cytomegalovirus (CMV) DNA positive or above the detection limit; Individuals who are positive for syphilis antigen or antibody. * 7\. Vaccination with attenuated live vaccine or protein subunit vaccine within 30 days prior to the first study use. * 8\. Women who are currently pregnant, breastfeeding, or planning to become pregnant. * 9\. The researchers believe that there are other situations that are not suitable for participating in this clinical study.